OCL
LOE Approachingpolyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate
NDAORALSOLUTION
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCL is an oral solution containing polyethylene glycol 3350, potassium chloride, sodium bicarbonate, sodium chloride, and sodium sulfate used for bowel cleansing prior to colonoscopy and other GI procedures. It works as an osmotic laxative that draws water into the intestines to facilitate complete evacuation of the bowel. This is a foundational gastrointestinal preparation product with decades of clinical use.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, indicating defensive positioning and potential team downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Started Aug 2026
32 enrolled
Acute Myeloid LeukemiaTP53 Gene Mutation
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Started Jul 2026
48 enrolled
Leukemia, MyeloidLeukemiaAcute Myeloid Leukemia+1 more
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Started Jun 2026
40 enrolled
HIV-1-infection
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Started May 2026
25 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Worked on OCL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.